Survodutide
Also called BI 456906, BI456906.
Survodutide is still investigational, with no FDA-approved product. This page cites 2 sources, and the strongest evidence comes from human trials.
- Status
- Investigational
- Form
- Injection
- Half-life
- Not modeled
- Strongest evidence
- Human trials
- Cited claims
- 2
- Last updated
- November 6, 2026
What the evidence says
Each claim names the kind of study behind it, what it can't tell you, and where it comes from.
Human trials
SYNCHRONIZE-1 randomized 725 adults without diabetes. At 76 weeks, mean weight reductions were 12.2% and 13.0% with weekly subcutaneous survodutide versus 5.4% with placebo under the treatment-regimen analysis.
Limits: Participants had obesity or overweight with a complication and received lifestyle counseling. Gastrointestinal events were common. These estimates include treatment discontinuation and differ from analyses assuming continued treatment. The trial does not establish cardiovascular benefit.
Human trials
SYNCHRONIZE-2 randomized 752 adults with type 2 diabetes and BMI at least 27. At 76 weeks, weight reductions were 8.2% and 9.8% with survodutide versus 3.9% with placebo under the treatment-regimen analysis.
Limits: These estimates account for interruptions, discontinuation, and other obesity treatments. Sponsor headlines using the efficacy estimand report larger losses. Gastrointestinal events were common, and the trial did not establish reductions in cardiovascular events or mortality.
Regulatory status
United States
Survodutide remains investigational and has no FDA-approved product as of November 6, 2026. Boehringer Ingelheim reports phase 3 development under the code BI 456906. Published obesity results do not establish an approved indication, product label, or personal treatment regimen.